CVS Health (CVS) closed at $66.6 in the latest trading session, marking a -4.28% move from the prior day.
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
CNBC's Angelica Peebles reports on news regarding CVS.
With the first half of 2025 wrapped up, now feels like as good a time as any to check in with the top-performing dividend plays and see how the stage is set for the rest of the year.
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
The S&P 500 is one of the most widely known benchmarks. It contains the 500 most valuable publicly traded U.S.
CVS Health (CVS) closed the most recent trading day at $67.58, moving +1.15% from the previous trading session.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.